scholarly journals Infantile Hemangioma Treated with Oral Propranolol: Case Presentation

2021 ◽  
Vol Volume 14 ◽  
pp. 1053-1055
Author(s):  
Nahid Raufi ◽  
Arash Nemat
Author(s):  
Prasetyanugraheni Kreshanti ◽  
Nandya Titania Putri ◽  
Valencia Jane Martin ◽  
Chaula Luthfia Sukasah

2017 ◽  
Vol 59 (8) ◽  
pp. 869-877 ◽  
Author(s):  
Tsuyoshi Kaneko ◽  
Satoru Sasaki ◽  
Naoko Baba ◽  
Katsuyoshi Koh ◽  
Kiyoshi Matsui ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-6
Author(s):  
Chuan Wang ◽  
Qi Wang ◽  
Bo Xiang ◽  
Siyuan Chen ◽  
Fei Xiong ◽  
...  

Background. The aim of this study was to examine whether oral propranolol has any effect on neurodevelopment outcomes in young children with problematic infantile hemangiomas (IHs). Methods. Thirty-six children with a diagnosis of problematic IH who were treated with oral propranolol were compared with 34 healthy children with no history of propranolol therapy. Patients received propranolol therapy for at least 3 months. Gesell developmental schedules (GDS) were used to evaluate neurodevelopment outcomes in the two groups. The scores of each GDS domain were compared between the two groups. Results. There were no significant differences in developmental quotient (DQ) values for any of the five domains between the patients and healthy controls (P<0.05). Multiple stepwise regression analyses showed that none of the domains in the control group were influenced by the children’s gender or age (P<0.05). In addition, we found that gender, age at the initiation of therapy, age at the time of the neurodevelopment test, and treatment duration had no effect on any domain of the GDS in the patient group (P>0.05). Conclusion. Propranolol has no obvious effect on neurodevelopmental outcomes in children. Early treatment and treatment duration had no negative effect on central nervous system (CNS) development.


2019 ◽  
Vol 46 (5) ◽  
pp. 376-382
Author(s):  
Zhang Yu ◽  
Ren Cai ◽  
Lei Chang ◽  
Yajing Qiu ◽  
Xuanfeng Chen ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
T. M. Morgan ◽  
J. M. Colazo ◽  
L. Duncan ◽  
R. Hamid ◽  
K. M. Joos

Background. Oculofaciocardiodental (OFCD) syndrome is due to mutations in BCOR (BCL-6 corepressor). OFCD has phenotypic overlaps with PHACE syndrome (Posterior fossa anomalies, Hemangioma, Arterial anomalies, Cardiac defects, Eye anomalies). Infantile hemangiomas are a key diagnostic criterion for PHACE, but not for OFCD. A previous study reported two cases of infantile hemangiomas in OFCD, but the authors could not exclude chance association. Case Presentation. We describe two novel cases of female patients (one initially diagnosed with PHACE syndrome), both of whom had infantile hemangiomas. Ophthalmological findings were consistent with oculofaciocardiodental (OFCD) syndrome. Upon genetic testing, these two females were determined to have X-linked BCOR mutations confirming OFCD syndrome diagnoses. Conclusion. These case reports add support to the hypothesis that infantile hemangiomas may be a feature of OFCD. BCOR may potentially be within a pathway of genes involved in PHACE syndrome and/or in infantile hemangioma formation.


2015 ◽  
Vol 62 (2) ◽  
pp. 518-519 ◽  
Author(s):  
C. Léauté-Labréze ◽  
P. Hoeger ◽  
J. Mazereeuw-Hautier

PEDIATRICS ◽  
2016 ◽  
Vol 138 (4) ◽  
pp. e20160353-e20160353 ◽  
Author(s):  
C. Leaute-Labreze ◽  
O. Boccara ◽  
C. Degrugillier-Chopinet ◽  
J. Mazereeuw-Hautier ◽  
S. Prey ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document